Committees’ consolidated opinions available on applications for authorisation
New committee’s consolidated opinions on applications for authorisation are available.
The applications are for four uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated by Sanofi Pasteur, Merck Biodevelopment SAS and FUJIFILM Diosynth Biotechnologies UK Limited, Swords Laboratories, and by Cytiva Sweden AB.